FDA Approved: KEPPRA XR — Supplemental Application (UCB, Inc.)

View source ↗

Summary

FDA approved a supplemental application to add KEPPRA XR, an extended-release formulation of levetiracetam, to the UCB product line.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• KEPPRA XR (levetiracetam)

Snippet

SUPPL AP for KEPPRA XR (LEVETIRACETAM)